|
 |
|
|
|
| |
|
|
|
|
| Table 13. HIV-infected patients currently prescribed primary
Pneumocystis carinii pneumonia (PCP) prophylaxis by data source and insurance status*
|
|
|
|
|
View PDF
|
|
Data in Tables 11-13 are based on the following analyses:
- In ASD (1999) and SHDC (1998), what proportion of eligible1 patients were prescribed primary prophylaxis for PCP?
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Data Source |
Total |
|
White |
|
Black |
|
Hispanic |
|
Asian/Pacific
Islander |
|
American Indian/
Alaska Native |
| % |
Treated/
Eligible |
% |
Treated/
Eligible |
% |
Treated/
Eligible |
% |
Treated/
Eligible |
% |
Treated/
Eligible |
% |
Treated/
Eligible |
| ASD* |
60 |
2,848/4,771 |
|
53 |
790/1,484 |
|
64 |
1,372/2,130 |
|
59 |
627/1,056 |
|
56 |
30/54 |
|
63 |
22/35 |
| SHDC Site A |
55 |
96/174 |
53 |
45/85 |
50 |
23/46 |
— |
— |
— |
— |
— |
— |
| SHDC Site B |
58 |
73/125 |
45 |
25/56 |
60 |
97/162 |
— |
— |
— |
— |
— |
— |
| SHDC Site C |
67 |
136/203 |
69 |
74/107 |
76 |
67/88 |
— |
— |
— |
— |
— |
— |
|
|
|
|
*Persons with unknown insurance status are not included. |
- Overall, between 55-67% of patients eligible to receive PCP prophylaxis were currently prescribed it.
- Greater proportions of eligible patients were prescribed PCP prophylaxis at SHDC Site C compared with the other data sources.
- For ASD and SHDC Site B, lesser proportions of patients with private insurance were prescribed PCP prophylaxis compared with patients with public insurance and with no insurance. ASD facilities include several large public hospitals and clinics that treat patients with HIV/AIDS, likely resulting in larger proportions of eligible patients with public insurance being prescribed PCP prophylaxis compared with patients with private insurance.
- Similar proportions of patients with public insurance and no insurance were prescribed PCP prophylaxis in ASD and SHDC Site A. This may be due to the populations represented by the samples at the 3 SHDC sites (see
Technical Notes). Sites A and B may contain more providers in and near metropolitan areas that routinely provide HIV-related care and may be more likely to prescribe prophylaxis regardless of the patient’s insurance status.
- Data from the SHAS and MOPTB studies were not available for this question.
|
|
|
|
|
|
|
|
|
|
|
